Associations of a breast cancer polygenic risk score with tumor characteristics and survival.

• DOI: 10.1200/jco.2022.40.16_suppl.563
• Publication Date: 2022-06-06T15:51:47Z
• Authors: Josephine Lopes C...; Irene L. Andrulis; Devilee Peter; Thilo Dörk; Caroline Drukker; Peter A. Fasching; Maartje J. Hooning; Renske Keeman; Heli Nevanlinna; Emiel J. Rutgers; Laura van 't Veer; Per Hall; Stig Egil Bojesen; Easton Douglas; Diana Eccles; Paul Pharoah; Marjanka Schmidt
• Keywords: Oncology and Carcinogenesis; Clinical Sciences; 610; Breast Neoplasms; 03 medical and health sciences; 0302 clinical medicine; SDG 3 - Good Health and Well-being; Risk Factors; Breast Cancer; Genetics; Humans; Oncology & Carcinogenesis; Breast; 10. No inequality; Cancer; Proportional Hazards Models; Biomedical and Clinical Sciences; Breast Cancer Association Consortium and MINDACT Collaborators; Prevention; Human Genome; Oncology and carcinogenesis; Prognosis; 3. Good health; Good Health and Well Being; Women's Health; Female

563 Background: A polygenic risk score (PRS) consisting of 313 single nucleotide polymorphisms (PRS313) is associated with risk of breast cancer and contralateral breast cancer. One of the most promising clinical applications for the use of PRS is to provide a personalized risk assessment to individualize breast cancer screening programs. This study aimed to evaluate the association of the PRS313 with clinical-pathological characteristics and survival of breast cancer. Methods: Women of European ancestry with invasive breast cancer were included, 98,397 women from the Breast Cancer Association Consortium (BCAC) and 683 women from the MINDACT trial. Associations between PRS313 (continuous, per SD) and clinical-pathological characteristics, including the 70-gene signature for patients included in MINDACT, were evaluated with logistic regression analyses. Associations of PRS313 with overall survival (OS), breast cancer-specific survival (BCSS) and distant metastasis-free interval (DMFI) were evaluated with Cox regression analyses, adjusted for clinical-pathological characteristics and treatment. Results: The PRS313 was associated with favorable tumor characteristics. In BCAC, increasing PRS313 was mostly associated with lower grade, hormone receptor-positive tumors, and with smaller tumor size. In MINDACT, PRS313 was associated with a low risk 70-gene signature, but the association was attenuated after adjustment for clinical-pathological characteristics. In BCAC, univariable analyses showed an association of PRS313 with better survival, hazard ratio (HR) per unit SD increase of PRS313 for OS: 0.96 (95% confidence interval (CI): 0.94-0.97), for BCSS HR: 0.96 (95% CI: 0.94-0.98) and for DMFI HR: 0.98 (95% CI: 0.96-1.00). The association in the unadjusted analysis was explained by differences in clinical-pathological characteristics (and treatment) and disappeared after adjustment: OS HR: 1.01 (95% CI: 0.98-1.05), BCSS HR: 1.02 (95% CI: 0.98-1.07) and DMFI HR: 1.03 (95% CI: 0.99-1.07). Conclusions: An increased PRS313 is associated with favorable tumor characteristics but was not independently associated with prognosis. This information is crucial input for modelling effective stratified screening programs, especially in the current era of optimized (systemic) treatments. Given the significant increase in breast cancer risk associated with increasing PRS313, absolute breast cancer mortality will still be higher for women with higher PRS313.